Alimera to present Iluvien Phase 3 clinical trial data at AAO annual meeting Alimera Sciences.

Iluvien is Alimera’s investigational intravitreal insert being studied for diabetic macular edema . The display, by Baruch Kuppermann, M.D., Ph.D, professor and chief of the Retina Service at University of California, Irvine, is slated for 4:19 p.m., Saturday, October 16, during the Retina 2010 subspecialty day system. Alimera has carried out two Phase 3 pivotal medical trials for Iluvien involving 956 patients in sites over the United States, Canada, India and Europe to assess the efficacy and protection of Iluvien with two doses, a higher and low dose, in the treatment of DME. Related StoriesMedflow announces availability of advanced cloud-centered EHR systemAAO recognizes excellent eye physicians and surgeons for invention in patient careNightstar announces $35 million Series B funding roundThe data in Dr.‘If you don't keep up a healthy lifestyle, you'll see the evidence when it comes to your risk of heart disease,’ Spring said. Because of this paper, scientists examined healthful life style behaviors and coronary artery calcification and thickening among the a lot more than 5,000 individuals in the Coronary Artery Risk Development in Young Adults study who had been assessed at baseline and 20 years later.